We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

BLRX Initiates Phase 2a Trial of BL-8040 with KEYTRUDA®

News   Sep 21, 2016

 
BLRX Initiates Phase 2a Trial of BL-8040 with KEYTRUDA®
 
 
Advertisement
 

RELATED ARTICLES

Oncogene Responsible for Deadly Glioblastoma Identified

News

Scientists have identified an oncogene AVIL responsible for glioblastoma, the deadliest brain tumor. The discovery offers a promising new treatment target.

READ MORE

Imaging Mass Spectrometry Identifies Carcinoma Tumor Markers

News

Researchers have used MALDI imaging mass spectrometry and immunohistochemistry to seek tumor-specific expression of proteins and lipids.

READ MORE

Trial Assessing Antiviral Drug DAS181 Against COVID-19 Begins Enrolling Patients

News

Keck Medicine of USC physicians are enrolling patients as part of an international clinical trial, designed to assess the safety and efficacy of the antiviral drug DAS181, as a possible treatment for patients with severe COVID-19.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Diagnostics Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE